罗非昔布

罗非昔布或罗非考昔（英語：，/ˌrɒf[不支援的輸入]ˈkɒksɪb/）商品名Vioxx、Ceoxx和Ceeoxx。是一种非甾体类抗炎药（NSAID），由默克公司製造、出售。美国食品药品监督管理局（FDA）于1999年5月20日批准上市，用以治疗骨关节炎、急性疼痛和痛经。

维基百科中的醫療相关内容仅供参考，詳見醫學聲明。如需醫療服務或可靠意見，请咨询专业人士。
罗非昔布
系统（IUPAC）命名名称
4-(4-methylsulfonylphenyl)-3-phenyl-5H-furan-2-one
临床数据
妊娠分级
  • AU: C
给药途径oral
合法狀態
合法状态
药代动力学数据
生物利用度93%
蛋白结合度87%
代谢hepatic
生物半衰期17 hours
排泄biliary/renal
识别
CAS注册号162011-90-7  
ATC代码M01AH02
PubChemCID 5090
DrugBankDB00533 
ChemSpider4911 
UNII0QTW8Z7MCR 
KEGGD00568 
ChEBICHEBI:8887 
ChEMBLCHEMBL122 
化学
化学式C17H14O4S
摩尔质量314.357 g/mol

由於發現到長期且高劑量用藥有增加心臟病的風險[1][2]，默克公司於2004年9月30日起從市場撤回此藥。

合成
罗非昔布的合成[3]

注脚
  1. 偉克適致死 藥廠賠10億
  2. 食品藥物釣愚：《釣愚：操縱與欺騙的經濟學》選摘（3）-食安｜藥物｜釣愚：操縱與欺騙的經濟學-風傳媒-喬治．艾克羅夫, 羅伯．席勒
  3. . Vioxxlawyer.org. [4 January 2015]. （原始内容存档于2015年1月5日）.

参考文献
  • FDA (2005). "Summary minutes for the February 16, 17 and 18, 2005, Joint meeting of the Arthritis Advisory Committee and the Drug Safety and Risk Management Advisory Committee." Published on the internet, March 2005. Link
  • Fitzgerald GA, Coxibs and Cardiovascular Disease, N Engl J Med 2004;351(17): 1709–1711. PMID 15470192.
  • Grassley CE (15 Oct 2004). Grassley questions Merck about communication with the FDA on Vioxx. Press Release.
  • Jüni P, Nartey L, Reichenbach S, Sterchi R, Dieppe PA, Egger M (2004). Risk of cardiovascular events and rofecoxib: cumulative meta-analysis. Lancet (published online; see also Merck response below)
  • Karha J and Topol EJ. The sad story of Vioxx, and what we should learn from it Cleve Clin J Med 2004; 71(12):933-939. PMID 15641522
  • Michaels, D. (June 2005) DOUBT Is Their Product Archive.is的存檔，存档日期2006-03-21, Scientific American, 292 (6).
  • Merck & Co., (5 Nov 2004). Response to Article by Juni et al. Published in The Lancet on Nov. 5. Press Release.
  • Merck & Co (30 Sep 2004) Merck Announces Voluntary Worldwide Withdrawal of VIOXX. Press release .
  • D. M. Mukherjee, S. E. Nissen, and E. J. Topol, "Risk of Cardiovascular Events Associated with Selective COX-2 Inhibitors," Journal of the American Medical Association 186 (2001): 954–959.
  • Nussmeier NA, Whelton AA, Brown MT, Langford RM, Hoeft A, Parlow JL, et al. Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery. N Engl J Med 2005;352(11):1081-91. PMID 15713945
  • Okie, S (2005) "Raising the safety bar--the FDA's coxib meeting." N Engl J Med. 2005 Mar 31;352(13):1283-5. PMID 15800221.
  • Leleti Rajender Reddy, Corey EJ. Facile air oxidation of the conjugate base of rofecoxib (Vioxx), a possible contributor to chronic human toxicity Tetrahedron Lett 2005, 46: 927. doi:10.1016/j.tetlet.2004.12.055
  • Swan SK et al., Effect of Cyclooxygenase-2 Inhibition on Renal Function in Elderly Persons Receiving a Low-Salt Diet. Annals of Int Med 2000; 133:1–9
  • Targum, SL. (1 Feb. 2001) Review of cardiovascular safety database. FDA memorandum.
  • Wolfe, MM et al., Gastrointestinal Toxicity of Nonsteroidal Anti-anflamattory Drugs, New England Journal of Medicine. 1999; 340; 1888-98.

外部链接
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.